Buy Rating for GH Research Driven by Promising TRD Program Developments and Regulatory Progress

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on GHRS stock, giving a Buy rating on August 8.

Patrick Trucchio has given his Buy rating due to a combination of factors related to GH Research’s promising developments in their treatment-resistant depression (TRD) program. The company is advancing its lead product, GH001, towards a pivotal Phase 3 program, which is expected to commence in 2026. The recent Phase 2b trial and open-label extension data have shown a rapid onset of action, a high remission rate, and a favorable safety profile, which differentiate GH001 from other treatments.
Furthermore, regulatory progress is being made, with the U.S. clinical hold narrowed to a single issue, and efforts are underway to resolve it. The ongoing Phase 1 study in the UK is also crucial for bridging the proprietary aerosol delivery device to existing clinical data, which will support global regulatory submissions. These developments, along with potential catalysts such as the initiation of the pivotal program and resolution of the IND hold, are expected to unlock significant shareholder value, justifying the Buy rating and the $40 price target.